JP2011116759A - Hyaluronic-acid accumulation accelerating composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a hyaluronic-acid accumulation accelerating agent having moisturizing effect of skin, preventing/improvement effect of rough dry skin, improvement effect of skin barrier function, improvement effect of skin wrinkle, and improvement/therapeutic effect of dry eye, and to provide a hyaluronic-acid accumulation accelerating composition containing thereof. <P>SOLUTION: The hyaluronic-acid accumulation accelerating composition contains a longan. The composition containing the hyaluronic-acid accumulation accelerating agent is used for moisturizing of skin, preventing/improvement of rough dry skin, preventing of skin aging such as wrinkle, loosening, and tone and preventing and treating dry eye. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention comprises a hyaluronic acid accumulation promoter comprising longanic as an active ingredient, skin moisturizing function, rough skin prevention / amelioration function, skin barrier function, wrinkle improvement function, dry eye prevention / treatment function, and a composition containing the agent Related to things.

  Hyaluronic acid is a linear high-molecular polysaccharide in which DN-acetylglucosamine and D-glucuronic acid are alternately bound, and is widely distributed in connective tissues such as mammalian skin, blood vessels, joints, and ocular vitreous. A type of saminoglucan. In addition, it has a property of binding to a very large amount of water (see, for example, Non-Patent Document 1), and binds to collagen that plays the role of a column of an intercellular matrix, thereby connecting connective tissue, cartilage tissue and skin tissue. It is distributed in large numbers and helps maintain the function and morphology of cells.

  In skin tissue, hyaluronic acid is abundant in the dermis layer and is greatly involved in the water retention and elasticity of the skin. However, due to aging and external stress, hyaluronic acid in the skin decreases or decreases in molecular weight, resulting in various types of rough skin such as dryness and roughness, formation of fine lines, sagging skin, loss of skin, etc. It is said to bring about aging.

  That is, by promoting the accumulation of hyaluronic acid in the living body, it is possible to improve rough skin, reduced skin barrier function, wrinkles, and the like caused by a decrease in the amount of hyaluronic acid produced.

  Therefore, as a method for improving such cases, attempts have been made to administer hyaluronic acid directly as an external preparation or an injection. However, hyaluronic acid is a high-molecular polysaccharide component, so transdermal absorption is low. In addition, replacement therapy with injections requires a doctor's prescription and is a painful treatment that can be used on a daily basis. is not.

  As external preparations for skin, technologies that promote the synthesis of hyaluronic acid (for example, see Patent Documents 1 to 3) or inhibit hyaluronidase that is a degrading enzyme (for example, see Patent Documents 4 to 6) have been disclosed so far. However, it is very difficult to increase the accumulation of hyaluronic acid, which is abundant in the dermis layer, because external preparations hardly act on the dermis layer.

  In addition, many beauty health foods that enhance the above-described effects by oral ingestion have been developed.

  Examples thereof include a technique for ingesting hyaluronic acid (for example, see Patent Document 7), a technique for ingesting N-acetylglucosamine, which is a constituent sugar of hyaluronic acid (for example, see Patent Document 8), and the like. However, it is necessary to ingest very large amounts of several hundred mg to several g in any case, and hyaluronic acid is expensive at a terminal price of several hundred thousand yen per kg. In terms of price, it is difficult to continuously take an effective amount as a beauty health food.

  On the other hand, dry eye has been conventionally used as a general term for dry eye, tear reduction, and dry keratoconjunctivitis. However, since the category of the pathological concept of dry eye is broad and the cause is often unknown, dry eye has been regarded as a wide variety of ocular surface diseases that should be called dry eye syndrome rather than a single disease. At present, dry eye is defined as a state in which the quantity or quality of tears is abnormal regardless of the presence or absence of keratoconjunctival disorder (see Non-Patent Document 2, for example). Diseases such as symptom, hypoxia, xerophthalmia, Sjogren's syndrome, dry keratoconjunctivitis, Stevens-Johnson syndrome, pemphigoid, blepharitis, closed eye failure, and sensory nerve palsy are included in the category of dry eye. In addition, dry eye related to allergic conjunctivitis, dry eye after viral conjunctivitis, dry eye after cataract surgery, and the like are also included in the category of the above dry eye.

  In recent years, dry contact has increased due to an increase in contact lens wearers, an increase in living time in an artificial air-conditioning environment, and an increase in opportunities to stare at VDT [video (visual) display terminal] screens due to the spread of televisions and personal computers. Factors that promote eyes are increasing, and dry eyes related to wearing contact lenses and dry eyes related to VDT work are increasing.

  One technique for determining dry eye is called the Schirmer test. This is performed by a technique in which a piece of filter paper meeting the standard is placed between the center of the lower eyelid and the 1/3 position on the ear side without local anesthesia. If the length of the filter paper wet with tears is 5 mm or less for 5 minutes in a row, diagnosis of tear-deficient dry eye is made (for example, see Non-Patent Document 3).

  At present, there is no causal therapy as a treatment method for dry eye, only symptomatic therapy is performed, and eye drops of artificial tears containing viscoelastic substances such as hyaluronic acid are mainly used.

  However, these substances are physically and physiologically different from mucins, which are inherently sticky proteins and have the function of fixing tears to the surface of the eye, so their therapeutic effects are limited. The burden on the patient of instilling once every few hours is also great.

  Moreover, when the symptoms of dry eye cannot be controlled by eye drop therapy, attempts have been made to close the punctum with a punctum plug (see Non-Patent Document 4, for example). The purpose of this is to increase the amount of intraocularly stored tears by inserting a silicone plug into the punctum area. Depending on the symptom, the upper or lower punctum or both upper and lower punctum is closed. However, it is still not a general treatment, and the physical and psychological burden on the patient is also great. As described above, there are still no satisfactory treatments and therapeutic agents for dry eye.

JP-A No. 13-163794 Japanese Patent Laid-Open No. 13-114637 JP-A-12-136147 JP-A-12-178196 Japanese Patent Laid-Open No. 11-21247 JP-A-9-241150 JP 2002-356432 A JP 2001-48789 A

Teruzo Miyoshi et al., Bio Industry, Vol. 11, p632-642, 1994. Bulletin of Japanese Ophthalmology, Vol. 11, p1289-1293, 1992. PRACTICAL OHTHALMOLOGY, Vol. 1, No. 1 9, p54-60, 1998. PRACTICAL OHTHALMOLOGY, Vol. 1, No. 1 9, p94-103, 1998.

  An object of the present invention is to provide a hyaluronic acid accumulation promoter having a skin moisturizing effect, a rough skin prevention / improving effect, a skin barrier function improving effect, a skin wrinkle improving effect, a dry eye improving / treating effect, and a hyaluronic acid containing the same It is to provide a composition for promoting accumulation.

  The present inventors have intensively studied in order to solve these problems, and orally ingesting Ryugannik can improve the skin moisturizing function, rough skin, skin barrier function, wrinkles, sagging, and develop a skin beautifying effect. And the present invention was completed by finding that dry eye can be prevented and improved.

The present invention
1. Hyaluronic acid accumulation promoter, characterized by containing longanganic and / or an extract thereof,
A composition for moisturizing skin, preventing or improving rough skin, a skin barrier, improving wrinkles and / or preventing or improving skin aging, comprising the hyaluronic acid accumulation promoter according to 2.1.
3.1 A composition for preventing and treating dry eye comprising the hyaluronic acid accumulation promoter according to 3.1,
4). The composition according to 1 to 3, comprising at least one selected from the group consisting of hyaluronic acid, ceramide, N-acetylglucosamine and glucosamine,
5. The composition according to any one of 1 to 4, which is a food,
6). 5. The composition according to any one of 1 to 4, which is a medicine,
About.
That is, a hyaluronic acid accumulation promoter characterized by containing longannik, and a skin moisturizing, rough skin prevention / improvement, skin aging prevention, dry hair characterized by containing this hyaluronic acid accumulation promoter. It is a composition for eye prevention / treatment.

  The hyaluronic acid accumulation promoter characterized by containing longan nik, which is the present invention, increases the moisturizing effect of the skin when taken orally, resulting in reduced barrier function derived from drying and intercellular lipids Skin roughness is remarkably improved, and skin aging such as wrinkles and sagging of the skin caused by a decrease in extracellular matrix such as hyaluronic acid constituting the dermis layer of the skin can be improved. The product of the present invention can be provided as a very inexpensive product compared to conventional collagen preparations and the like.

  In addition, dry eye symptoms such as dry eyes, dry eyes, easily tiring eyes, heavy eyes, and congested eyes can be alleviated and dry eyes can be prevented and improved.

  Ryugannik is also a food material with a long dietary experience, and it is very safe and can be taken in an effective amount with peace of mind.According to the present invention, hyaluronic acid accumulation is extremely excellent in terms of safety and economy. It is possible to provide a composition for moisturizing skin, for preventing and improving rough skin, for preventing skin aging, and for preventing and treating dry eye by promoting effects.

  It has not been known that dry or extract of Ryugannik has an action to promote hyaluronic acid accumulation, thereby improving skin moisture, rough skin, skin barrier function, wrinkles and sagging, and dry eyes. It is a completely new finding obtained by the present invention that it is also effective in preventing and improving the above.

Results of evaluation of hyaluronan accumulation promotion in cells by negatively charged colloid exclusion method (when Ryuganic extract is not applied: control). The part that appears white is the hyaluronic acid accumulation part. Evaluation results of hyaluronic acid accumulation promotion in cells by negative charged colloid exclusion method (when phorbol ester 100 nM is applied). Evaluation result of hyaluronic acid accumulation promotion in cells by negative charged colloid exclusion method (when dexamethasone 10 nM is applied). Evaluation result of hyaluronic acid accumulation promotion to cells by negative charged colloid exclusion method (when Ryugannik extract 0.05 mg / ml is applied). Evaluation result of hyaluronic acid accumulation promotion in cells by negative charged colloid exclusion method (when Ryuganic extract 0.5 mg / ml is applied). Evaluation result of hyaluronic acid accumulation promotion to cells by negative charged colloid exclusion method (when Ryugannik extract 5 mg / ml is applied). The quantitative evaluation result of the hyaluronic acid accumulation promotion effect in the fibroblast by Ryugannik extract. Results of skin moisturizing evaluation by continuous use of Ryugannik extract combination preparation. Evaluation results of skin barrier function and rough skin by continuous ingestion of Ryugannik extract combination preparation. The skin elasticity evaluation result by continuous ingestion of a preparation containing Ryugannik extract. Evaluation results of skin barrier function and rough skin by continuous ingestion of Ryugannik extract combination preparation (8 weeks) Evaluation results of skin barrier function and rough skin by continuous ingestion of Ryugannik extract combination preparation (8 weeks) (under 40 years old) Results of actual questionnaire (dry) after continuous use (8 weeks) of Ryugannik extract combination preparation Questionnaire results (dullness) by continuous intake (8 weeks) of Ryugannik extract combination preparation Results of a questionnaire survey on the long-term intake of Ryugannik extract (8 weeks) Questionnaire results (transparency) by continuous intake of Ryugannik extract formulation (8 weeks) Questionnaire results (comprehensive feeling) by continuous ingestion of Ryugannik extract combination preparation (8 weeks) Questionnaire results of eyes taken by continuous ingestion of Ryugannik extract formulation (8 weeks) (eye fatigue) Results of actual questionnaire (dry eyes) after continuous use (8 weeks) of Ryugannik extract combination preparation

  In the present invention, Ryugannik (dragon eye meat) is a name that refers to a temporary seed coat of Euphoria longan (Lour.) Steud. Herbal medicines that have been semi-dried from Nik) have been listed in the Chinese Pharmacopoeia and have been shown to have anxiolytic, memory-improving, antibacterial, immune-enhancing, and tonic effects (Tradition and Medicine, Vol. .4, 1999).

  Ryugannik in the present invention is a dried product, a pulverized product thereof, a squeezed juice obtained by squeezing and extracting itself, a crude extract of water or an organic solvent such as alcohol, ether or acetone, and a crude extract. An extract fraction obtained by stepwise purification by partitioning, column chromatography or the like can be used. These may be used alone or in combination of two or more. A cultivation method and a cultivation place are not particularly limited.

  For example, an extract obtained by adding 3 L of ethanol to 1 kg of a dry plant of Ryugannik and immersing it overnight at room temperature may be used as it is as a skin activator having a hyaluronic acid accumulation promoting effect. You may use what was refine | purified combining liquid partition and various chromatography.

  Hyaluronic acid is an acidic mucopolysaccharide having a viscosity of about 500,000-3 million. Hyaluronic acid is contained in a large amount (about 1%) in, for example, a chicken crown, and this chicken crown has been used for food since ancient times. In order to industrially produce hyaluronic acid, for example, there are an extraction method using living tissue as a raw material and a fermentation method using microorganisms. Moreover, you may use those salts.

  Ceramide is a naturally occurring ceramide having a structure in which sphingosine, fatty acid and sugar are bound, for example, extracted from animal-derived bovine brain, plant-derived wheat, rice, soybean, rice bran, spinach, etc. Examples include those extracted from microorganisms such as yeast. This ceramide can be obtained by a known method. For example, a method of extracting from wheat or rice bran as a raw material using a polar solvent such as ethanol, acetone and water and recrystallizing in an organic solvent.

  N-acetylglucosamine or glucosamine can be obtained by hydrolyzing natural polysaccharide chitin derived from the shell of crustaceans such as crabs and shrimps using known methods such as acid and enzyme. Moreover, you may use those salts.

  In the present invention, by using Ryugannik in combination with hyaluronic acid, ceramide, N-acetylglucosamine, and glucosamine, a higher hyaluronic acid accumulation promoting effect can be brought about.

  Using the agent of the present invention, a composition for improving rough skin, preventing skin aging and improving dry eye, and a medicine or food containing these can be produced.

  The hyaluronic acid accumulation promoting agent or hyaluronic acid accumulation promoting composition of the present invention can be applied as a food. As a food, it can be eaten as a food material as it is or with various nutritional components added or contained in a food or drink. For example, after adding suitable auxiliaries such as starch, lactose, maltose, vegetable oil powder, cocoa butter powder, stearic acid, etc., using conventional means, edible forms such as granules, granules, tablets It may be formed into capsules, pastes, etc. and used for food, and various foods such as processed foods such as ham and sausage, fishery processed foods such as kamaboko and chikuwa, bread, confectionery, butter, milk powder, fermented milk It may be used by adding to dairy products or by adding to beverages such as water, fruit juice, milk, soft drinks and tea.

  In the present invention, effective doses of Ryugannik, which is an active ingredient, and further hyaluronic acid, ceramide, N-acetylglucosamine, glucosamine are the patient's age, body weight, symptoms, patient grade, administration route, administration schedule, formulation form, It is appropriately selected depending on the strength of the inhibitory activity of the material, etc., preferably 10 to 1,500 mg for Ryuganic, 1 to 100 mg for hyaluronic acid, 0.1 to 10 mg for ceramide, 0.1 to 10 mg for N-acetylglucosamine and glucosamine per day The dose may be about 1-1,500 mg, and may be administered in several divided doses per day.

Hereinafter, the present invention will be specifically described with reference to examples. However, the present invention is not limited to these examples.
[Example 1: Extraction of plant]
1 kg of a temporary seed coat part (longanic) of longan (Euphoria longan (Lour.) Steud.) Was shredded, 3 L of water was added, and it was immersed overnight at room temperature. This was filtered to obtain an extract. When the extract was concentrated, each evaporation residue was 250 g.
[Example 2: Extraction of plant]
1 kg of a temporary seed coat (longanic) of longan (Euphoria longan (Lour.) Steud.) Was shredded, 3 L of 99.5% ethanol was added, and the mixture was immersed at room temperature overnight. This was filtered to obtain an extract. When the extract was concentrated, the evaporation residue was 75 g.

  Hereinafter, the formulation examples will be described in detail, but the present invention is not limited thereto.

[Prescription Example 1: Manufacture of tablets]
Using the aqueous extract of Ryugannik obtained in Example 1, tablets having the following composition were produced according to a conventional method.
(Composition) (Composition: Weight%)
Ryugannik extract 50.0
Lactose 37.0
Cornstarch 12.0
Guar gum 1.0

[Prescription Example 2: Manufacture of tablets]
Using the aqueous extract of Ryugannik obtained in Example 1, tablets having the following composition were produced according to a conventional method.
(Composition) (Composition: Weight%)
Ryugannik extract 16.7
Lactose 62.1
Corn starch 20.2
Guar gum 1.0

[Prescription Example 3: Manufacture of tablets]
Using the aqueous extract of Ryugannik obtained in Example 1, tablets having the following composition were produced according to a conventional method.
(Composition) (Composition: Weight%)
Ryugannik extract 25.0
N-acetylglucosamine 12.5
Hyaluronic acid 2.5
Ceramide 2.5
Cellulose 15.0
Starch 19.5
Vegetable oil and fat powder 3.0
Lactose 20.0

[Prescription Example 4: Manufacture of tablets]
Using the aqueous extract of Ryugannik obtained in Example 1, tablets having the following composition were produced according to a conventional method.
(Composition) (Composition: Weight%)
Ryugannik extract 25.0
Glucosamine 15.0
Ceramide 2.5
Cellulose 15.0
Starch 19.5
Vegetable oil and fat powder 3.0
Lactose 20.0

[Formulation Example 5: Production of juice]
A juice having the following composition was produced in accordance with a conventional method using the aqueous extract of Ryugannik obtained in Example 1.
(Composition) (Composition: Weight%)
Frozen and concentrated Wenzhou orange juice 5.0
Fructose glucose liquid sugar 11.0
Citric acid 0.2
L-ascorbic acid 0.02
Fragrance 0.2
Dye 0.1
Ryugannik Extract 0.2
Water 83.28

The hyaluronic acid accumulation-promoting effect of longanic, which is the present invention, was confirmed by the following test method.
[Test Example 1: Hyaluronic acid accumulation promotion test]
Hyaluronic acid accumulation promoting action was evaluated by referring to a test using biotin-fixed erythrocyte suspension (Biochemistry 73 (2), 429-438 (2001)) and establishing an improved method, that is, negatively charged colloid exclusion method. . The details of the negatively charged colloid exclusion method are as follows.

Hyaluronic acid has a repeating structure of D-glucuronic acid and DN-acetylglucosamine, and the carboxyl group of the glucuronic acid has a negative charge throughout the hyaluronic acid. Since cells with hyaluronic acid have a negative charge in the presence of hyaluronic acid, adding a colloid solution with a negative charge to it causes the colloid to be printed at the site where hyaluronic acid is present by the repulsive force of the negative charge. ) Can be used to observe the printing of the colloid. The negatively charged colloid exclusion method is a test method for confirming the accumulation of hyaluronic acid by utilizing this property, and is an ELISA method (AJ Fosang et al., Matrix, 10, 306-) for checking the total amount of hyaluronic acid. 313, 1990), the anion colloid exclusion method is superior in that the state of the matrix can be visualized. Using this method, the amount of accumulated hyaluronic acid can be visually determined by the darkness and thickness of the print. When quantifying the printed part, that is, the part where hyaluronic acid is accumulated, it can be visualized as white because light is transmitted under the microscope, and other parts are observed as a dark background that does not transmit light with paint. Follow the procedure below.
(1) Import an image observed under a microscope into Scion Image, which is image analysis software.
(2) Convert each image to monochrome.
(3) Measure the area and brightness of the site that looks white (hyaluronic acid accumulation site).
(4) Randomly select three dark backgrounds near the hyaluronic acid accumulation site measured in (3), measure the lightness at that location, and calculate the average value.
(5) The absolute lightness (gray value) is calculated from (lightness of hyaluronic acid accumulation site−average value of lightness of 3 backgrounds) × area of hyaluronic acid accumulation site).
(6) The gray value at the time of administration of each test substance is calculated when the gray value of the untreated group is 100.
(7) The same operation is performed for all hyaluronic acid accumulation sites in the captured image, and the average value is calculated.

  Specifically, after culturing human skin fibroblasts on a tissue culture plate, the longan extract prepared in Example 1 was used at a concentration of 0, 0.05, 0.5, 5 mg / mL, and positive control. PMA (phorbol ester: manufactured by Sigma) as a negative control and DXM (dexamethasone: manufactured by Sigma) as a negative control were prepared so that PMA was 100 nM and DXM was 10 nM at final addition concentrations, and each was allowed to act for 16 hours. After the action, after removing the medium, 50 μL of anionic colloidal particle suspension at a concentration of 2.5 mg / mL (Holvine, 843 PERMANENT GREEN DEEP) was added, and the area was excluded by the hyaluronic acid-rich matrix of cells. Was observed under a microscope to determine the activity visually and quantitatively.

  The evaluation results for the hyaluronic acid accumulation promoting action of each sample are shown in FIG. 1 to FIG. 6, and the quantitative values are shown in FIG.

  From FIG. 1 to FIG. 6, compared to the control group without addition of Ryugannik extract (FIG. 1), it was observed as a hyaluronic acid accumulation site in the Ryugannik extract addition group (FIGS. 4 to 6) depending on the addition concentration. It can be observed that the white part is thicker or longer and the brightness (intensity of white) is enhanced.

In addition, as shown in FIG. 7 which is a result of quantitative evaluation of the results of FIGS. 1 to 6, 21% is obtained in the 0.5 mg / ml addition group of Ryugannik extract and 107% in the 5 mg / ml addition group. It can be seen that the amount of acid accumulation increases, and Ryugannik extract increases the amount of hyaluronic acid accumulation in human fibroblasts in a concentration-dependent manner.
[Test Example 2: Evaluation of effectiveness on skin by monitor]
Four tablets of Formulation Example 1 (300 mg per tablet) were ingested daily for 4 weeks continuously to 4 people who were chronically dry and had rough skin on a daily basis. The following three items were evaluated before intake, 2 weeks after the start of intake, and 4 weeks after the start of intake. In order to keep the measurement conditions the same as much as possible, the measurement was carried out after washing the face and resting in a temperature-controlled room at a room temperature of 21 ° C./humidity of 36% for 20 minutes.
[Evaluation item 1: Evaluation of skin moisturizing function]
The moisture content of the cheek was measured with SKICON-200 (IBS). The measured value is represented by electrical conductivity (μS), and the larger the value, the greater the amount of moisture. Therefore, the moisture retention function of the hyaluronic acid accumulation promoter of the present invention can be examined by measuring the moisture content of SKICON-200.

FIG. 8 shows the results of skin moisture measurement before ingestion, 2 weeks after the start of ingestion, and 4 weeks after the start of ingestion. By taking the tablets of Formulation Example 1, the moisture content of the skin increased by 9.9% 2 weeks after the start of intake and 45.0% after 4 weeks of the start of intake.
[Evaluation item 2: Evaluation of skin barrier function and rough skin]
It shows that the higher the value of transdermal moisture transpiration (TEWL), the lower the barrier function of the stratum corneum, causing rough skin. Therefore, the skin barrier function of the hyaluronic acid accumulation promoter of the present invention can be examined by measuring the TEWL value. The cheek was measured using a TEWA meter (Courage + Khazaka) for measurement.

FIG. 9 shows the results before intake, 2 weeks after the start of intake, and 4 weeks after the start of intake. By ingesting the tablet of Formulation Example 1, when the TEWL value before ingestion is taken as 100%, the transdermal water transpiration amount is 53.6% 2 weeks after the start of ingestion and 42.6% after 4 weeks of ingestion. Decreased, and the skin barrier function was restored.
[Evaluation item 3: Evaluation of skin elasticity (skin wrinkle, sagging, and beam)]
The skin elasticity of the cheek was measured using a cut meter (CUTOMETER SEM474, Courage + Khazaka). The value of elasticity decreases with aging and the like in a state where there is no sagging skin. Therefore, if the elasticity value increases, it becomes an index that means a tightened state in which the skin is more flexible and elastic. FIG. 10 shows the results before intake, 2 weeks after the start of intake, and 4 weeks after the start of intake.

  By taking the tablet of Formulation Example 1, the elasticity of the skin increased by 14.5% 2 weeks after the start of intake and 15.3% after 4 weeks of the start of intake.

From the above results, it was confirmed that ingestion of food containing Ryugannik improves skin moisturizing function, skin barrier function, rough skin, and skin elasticity (skin wrinkles, sagging, and elasticity). .
[Test Example 3: Evaluation of dry eye]
Daily three chronically dry eyed women were given 10 tablets of Formulation Example 1 (300 mg per tablet) daily for 4 weeks. Before and after the intake period, the following five scores were evaluated and evaluated as the main symptoms of dry eye: easy eye fatigue, heavy eyes, congested eyes, dry eyes, and dry eyes. It was. Table 1 shows the results before intake, 2 weeks after the start of intake, and 4 weeks after the start of intake. The lower the score value, the milder the symptoms of dry eye.

Score criteria for dry eye Symptoms are very worrisome = 2
I'm worried about symptoms = 1
I don't care about symptoms = 0

From the above results, it was confirmed that various symptoms of dry eye were improved by ingesting food containing Ryugannik.
[Test Example 4: Evaluation of effectiveness on skin by monitor (large-scale test)]
38 healthy women aged 20 to 65 years (1) 10 tablets each day of Formulation Example 1 tablets (300 mg per tablet), (2) 10 tablets each day of Formulation Example 2 tablets (300 mg per tablet) (3) Divided into 3 groups of placebos and ingested continuously for 8 weeks in a double blind (double blind comparison) test. Before intake, 4 weeks after the start of intake, and 8 weeks after the start of intake, the following items were evaluated and a questionnaire survey was conducted after the end of the study. In order to keep the measurement conditions the same as much as possible, the measurement was carried out after washing the face and resting in a temperature-controlled room at a room temperature of 21 ° C./humidity of 36% for 20 minutes.
[Evaluation item 1: Evaluation of skin barrier function and rough skin]
It shows that the higher the value of transdermal moisture transpiration (TEWL), the lower the barrier function of the stratum corneum, causing rough skin. Therefore, the skin barrier function of the hyaluronic acid accumulation promoter of the present invention can be examined by measuring the TEWL value. For measurement, a TEWA meter (Courage + Khazaka) was used to measure the upper arm.

The results before intake, 2 weeks after the start of intake, and 4 weeks after the start of intake are shown in FIGS. (1) High-capacity group (H group: 1,500 mg / day as longanic extract) intake group, when TEWL value before intake is 100%, 40.5 weeks after start of intake, 90.5%, start of intake 8 After a week, the transdermal water evaporation decreased to 75.9%, and the skin barrier function was restored. Furthermore, in the group of 40 years old or less, it decreased significantly (P <0.05) with respect to the placebo administration group (P group) of (3) at the 8th week of intake. In the low-volume group (2) (L group; 500 mg / day as longanic extract), the skin barrier function was restored to 82% after 8 weeks.
[Evaluation Item 2: Evaluation of Questionnaire Survey (Dry Skin, Dullness, Beam, Transparency, Comprehensive and Dry Eye)]
In each intake group, “skin dryness”, “dullness”, “beam”, “transparency”, “total skin effect”, “eye fatigue” and “eye dryness” after 8 weeks of ingestion A questionnaire survey was conducted. For each questionnaire, one was selected from three items: <Improved>, <No change>, and <Deteriorated>. For “Total skin effect”, select one of the following four items: <I felt>, <I felt slightly>, <I didn't feel much>, and <I didn't feel at all> received. Each questionnaire result is shown in FIGS.

In the high-capacity group of (1) (High; 1,500 mg / day as Ryugannik extract) and (2) the low-volume group (Low; 500 mg / day as Ryugannik extract) Compared with the placebo group (Placebo) of (3) in the items of “Dullness”, “Hari”, “Transparency”, “Overall skin effect”, “Fatigue of eyes”, “Dry eyes” There was a trend of improvement. The improvement trend increased depending on the intake of Ryugannik extract.

From the above results, it was confirmed that ingestion of food containing Ryugannik improved skin moisture retention function, skin barrier function, rough skin prevention / improvement, wrinkle improvement, skin aging prevention and dry eye. .

Claims (6)

  A hyaluronic acid accumulation promoter characterized by containing longangan and / or an extract thereof.   A composition for moisturizing skin, preventing and improving rough skin, for improving skin barrier, wrinkles and / or preventing and improving skin aging, comprising the hyaluronic acid accumulation promoter according to claim 1.   A composition for preventing and treating dry eye comprising the hyaluronic acid accumulation promoter according to claim 1.   4. The composition according to claim 1, further comprising at least one selected from the group consisting of hyaluronic acid, ceramide, N-acetylglucosamine, and glucosamine.   The composition according to any one of claims 1 to 4, which is a food.   The composition according to any one of claims 1 to 4, which is a medicine.